Working to Eradicate Gynecologic Cancers

Reshma Rangwala, MD, PhD

Associate Clinical Director
Merck Research Laboratories
PO Box 1000
351 N. Sumneytown Pike
North Wales, PA
USA 19454-1099

Papers:
448 - Poster Session B CA-125 as a response marker for vintafolide+pegylated liposomal doxorubicin vs pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer: the PRECEDENT trial 449 - Poster Session B Adverse event profile by folate receptor status for vintafolide+pegylated liposomal doxorubicin vs pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer